The term biomarker is used to describe a concept familiar to pathologists– a laboratory-measurable analyte which provides information useful in assessing the nature and extent of disease, the response to therapy, or the potential to respond to a proposed therapy.
The various named arthritic pathologies are well-diagnosed by current clinical and laboratory tests, yet there is room for improvement. There are various treatment options, ranging from aspirin to complex biologicals, admixed with treatment to reduce pain. Rheumatologists have established hierarchies of treatment, progressing from simpler to more complex and more expensive treatments depending on response. The aim of novel biomarker studies is to allow identification of the most appropriate treatment at the outset, based on laboratory testing, making the process more effective.
Due to the target values and convenience of measurement with automated technology within the era, the applications of biomarkers in biomedicine are increasingly broader and vastly important. Immunohistostaining of molecular markers are widely used for identifying cancer types. FLT3 and nucleophosmin (NPM1) mutations are playing important roles in individualizing treatment decisions on acute chronic myelocytic leukaemia. As an example, Oncotype Dx carcinoma test, a 21-gene panel assay, provides personalized prediction of carcinoma relapse risk and may potentially reduce unnecessary adjuvant chemotherapy. Targeted agents are revolutionizing the cancer therapy. Trastuzumab, a MoAb blocking Her2/neu, is an indispensible agent for Her2/neu positive carcinoma and metastatic gastric cancer. Bevacizumab, a MoAb binding vascular endothelial protein (VEGF), has been approved for the treatment of a broad spectrum of advanced malignancies like colorectal, brain, kidney and non-small cell lung cancer (NSCLC). Brentuximab vedotin (SGN-35), an immunotoxin conjugate, is now available for CD30 positive anaplastic large cell lymphoma and Hodgkin lymphoma.
Research Article: Molecular Biomarkers & Diagnosis
Research Article: Journal of Molecular Biomarkers & Diagnosis
Commentary: Molecular Biomarkers & Diagnosis
Commentary: Journal of Molecular Biomarkers & Diagnosis
Review Article: Molecular Biomarkers & Diagnosis
Review Article: Journal of Molecular Biomarkers & Diagnosis
Editorial: Molecular Biomarkers & Diagnosis
Editorial: Journal of Molecular Biomarkers & Diagnosis
Editorial: Molecular Biomarkers & Diagnosis
Editorial: Journal of Molecular Biomarkers & Diagnosis
Research Article: Molecular Biomarkers & Diagnosis
Research Article: Journal of Molecular Biomarkers & Diagnosis
Scientific Tracks Abstracts: Journal of Tissue Science and Engineering
Scientific Tracks Abstracts: Journal of Tissue Science and Engineering
Posters & Accepted Abstracts: Metabolomics:Open Access
Posters & Accepted Abstracts: Metabolomics:Open Access
Keynote: Metabolomics:Open Access
Keynote: Metabolomics:Open Access
Posters & Accepted Abstracts: Journal of Cytology & Histology
Posters & Accepted Abstracts: Journal of Cytology & Histology
Keynote: Metabolomics:Open Access
Keynote: Metabolomics:Open Access
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report